Table 2.

Drugs targeting TRP channels in clinical development

Action	Drug	Company	Therapy Area	Highest development status	ClinicalTrials.gov identifier
TRPV1 agonist	capsaicin	Not Assigned	Pain	Launched
TRPV1 agonist	NGX-4010	Acorda Therapeutics Inc/Astellas Pharma Inc	Postherpetic neuralgia	Launched
TRPV1 agonist	zucapsaicin	Sanofi-Aventis Canada Inc	Osteoarthritis	Registered
TRPV1 agonist	zucapsaicin	Winston Pharmaceuticals Inc	Cluster headache	Phase 3	NCT00033839
TRPV1 agonist	MCP-101 (resiniferatoxin)	Mt Cook Pharma	Overactive bladder	Phase 2	N/A
TRPV1 antagonist	DWP-05195	Daewoong Pharmaceutical Co Ltd	Neuropathic pain	Phase 2	NCT01557010
TRPV1 antagonist	XEN-D0501	Provesica Ltd	Overactive bladder	Phase 2	N/A
TRPV1 siRNA	SYL-1001	Sylentis Sau	Ocular pain	Phase 2	NCT01776658
TRPV1 antagonist	Mavatrep	Johnson & Johnson Pharmaceutical Research & Development LLC	Osteoarthritis/Pain	Phase 1	NCT00933582
					NCT01006304
TRPV1 antagonist	PHE-377	PharmEste SRL	Neuropathic pain	Phase 1	N/A
TRPV1 antagonist	MR-1817	Mochida Pharmaceutical Co Ltd	Pain	Phase 1	NCT00960180
TRPV1 antagonist	PAC-14028	Pacific Pharmaceuticals Co Ltd	Atopic dermatitis/IBD	Phase 1	NCT01638117
TRPV1 antagonist	SB-705498	GlaxoSmithKline plc	Pruritus	Phase 1	NCT01673529
TRPV3 antagonist	GRC-15300	Glenmark Pharmaceuticals Ltd/Sanofi	Neuropathic pain/Osteoarthritis	Phase 2	NCT01463397
TRPM8 agonist	Menthol	Not assigned	Carpal tunnel syndrome/Neck pain	N/A	NCT01716767
					NCT01542827
TRPM8 agonist	D-3263	Dendreon Corp	Cancer	Phase 1	NCT00839631
TRPA1 antagonist	GRC-17536	Glenmark Pharmaceuticals Ltd	Diabetic peripheral neuropathy/Respiratory disorders	Phase 2	NCT01726413
TRPA1 antagonist	CB-625	Cubist Pharmaceuticals/Hydra Biosciences	Inflammatory disease/ Pain	Phase 1	N/A